Biomarker Potential of Anti-Immunoglobulin Binding Protein in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Current Evidence and Future Directions

Authors

  • Ghada Sanad Nageeb, Lamiaa Abdelwahab Mohamed, Menna Bayomi Awad allah Tartour, Enas I. Abdelhady

Keywords:

Anti-Immunoglobulin Binding Protein, Rheumatoid Arthritis, Systemic Lupus Erythematosus

Abstract

Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are chronic, debilitating autoimmune diseases characterized by immune dysregulation, systemic inflammation, and multi-organ involvement. Despite advances in diagnostic tools and therapeutic strategies, early and accurate diagnosis, as well as reliable markers for disease activity, remain significant clinical challenges. Serum Anti-Immunoglobulin Binding Protein (Anti-BiP) antibodies have emerged as potential biomarkers with promising diagnostic and prognostic utility in both RA and SLE.

References

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.

Matcham F, Rayner L, Steer S. The impact of depression on rheumatoid arthritis outcomes. Arthritis Care Res.

;66(8):1205-1215.

Michaud K, Messer J, Wolfe F. Economic burden of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2750 2762.

Downloads

Published

2024-09-23

How to Cite

Ghada Sanad Nageeb, Lamiaa Abdelwahab Mohamed, Menna Bayomi Awad allah Tartour, Enas I. Abdelhady. (2024). Biomarker Potential of Anti-Immunoglobulin Binding Protein in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Current Evidence and Future Directions. Journal of Computational Analysis and Applications (JoCAAA), 33(06), 1422–1436. Retrieved from https://eudoxuspress.com/index.php/pub/article/view/1993

Issue

Vol. 33 No. 06 (2024): JOCAAA

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.